Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

394
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of Urine Sodium in Patients With Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.

Cureus·2026
Same author

Clinical significance of maturing vascular access for incident hemodialysis patients.

The journal of vascular access·2026
Same author

Cultural and systemic barriers in Parkinson's disease diagnosis, treatment, and research participation among Asian Americans: A qualitative study.

Journal of Parkinson's disease·2026
Same author

Alternative Measures of Body Composition and Outcomes Following Heart Transplant.

Clinical transplantation·2026
Same author

A Contemporary Guide of Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock.

Journal of cardiovascular development and disease·2025
Same author

Living liver donor safety: Early postoperative considerations of living liver donation guidelines from the ILTS-iLDLTG consensus conference.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025

Related Experiment Video

Updated: Jul 7, 2025

Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.7K

The Seattle Heart Failure Model in Kidney Transplant Recipients.

Angelica Perez-Gutierrez1, Rita L McGill2, Braden Juengel1

  • 1Department of Surgery, Transplant Institute, University of Chicago, Chicago, IL 60637, USA.

Journal of Clinical Medicine
|December 23, 2023
PubMed
Summary

The Seattle Heart Failure Model (SHFM) can predict mortality risk in kidney transplant candidates. An adapted SHFM score effectively identifies patients at higher risk for post-transplant death.

Keywords:
Seattle Heart Failure Modelcardiac riskkidney transplantmortality

More Related Videos

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents
06:33

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents

Published on: September 21, 2021

2.4K
An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
09:25

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

Published on: May 8, 2020

7.9K

Related Experiment Videos

Last Updated: Jul 7, 2025

Mouse Kidney Transplantation: Models of Allograft Rejection
16:15

Mouse Kidney Transplantation: Models of Allograft Rejection

Published on: October 11, 2014

20.7K
A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents
06:33

A Simplified Model for Heterotopic Heart Valve Transplantation in Rodents

Published on: September 21, 2021

2.4K
An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
09:25

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

Published on: May 8, 2020

7.9K

Area of Science:

  • Nephrology
  • Cardiology
  • Transplantation Medicine

Background:

  • Cardiovascular disease is the primary cause of death post-kidney transplant.
  • Heart failure is prevalent in chronic kidney disease patients, worsening with dialysis duration.
  • The Seattle Heart Failure Model (SHFM) predicts heart failure mortality but lacks kidney function parameters.

Purpose of the Study:

  • To evaluate the utility of an adapted Seattle Heart Failure Model (SHFM) in predicting post-transplant mortality in end-stage renal disease (ESRD) patients.
  • To assess the association between the adapted SHFM score and survival outcomes following kidney transplantation.

Main Methods:

  • Retrospective analysis of 360 adult deceased-donor kidney transplant recipients.
  • Application of the SHFM to patients with end-stage renal disease (ESRD) prior to transplantation.
  • Cox regression modeling to assess the relationship between the adapted SHFM score and post-transplant survival.

Main Results:

  • A 1.0-point increase in the adapted SHFM score was significantly associated with increased post-transplant mortality (HR 1.76, p=0.02).
  • This association remained significant, independent of Kidney Donor Profile Index and Estimated Post-Transplant Survival.
  • Age, sodium, cholesterol, and lymphocyte count were significant individual predictors of mortality.

Conclusions:

  • The adapted SHFM score shows promise as a tool for assessing mortality risk in ESRD patients awaiting kidney transplantation.
  • Incorporating kidney function assessment into mortality risk models may improve prediction for transplant candidates.